When and How to Publish Results on Clinical Trial Registries

Why Posting Trial Results Is a Regulatory Requirement

Results disclosure on public registries is not optional—it’s a mandated obligation governed by regulations such as FDAAA 801, EU Regulation 536/2014, and WHO best practices. Regulatory bodies like the FDA, EMA, and WHO expect timely posting of summary results to promote data transparency and uphold ethical standards for participant protection.

Failure to post results within the designated timeframe may lead to noncompliance notices, fines, rejection of future submissions, and reputational damage. Sponsors, investigators, and CROs all have defined responsibilities when it comes to registry result postings.

Deadlines for Results Posting on Different Registries

Each major trial registry has defined rules for the timing of results posting:

• ClinicalTrials.gov (USA): Summary results must be posted within 12 months of the “primary completion date.” Fines can exceed $10,000/day for non-compliance.
• EudraCT (EU legacy): Summary results must be posted within 12 months (or 6 months for pediatric trials) of trial end. Applies to trials under Directive 2001/20/EC.
• CTIS (EU CTR 536/2014): Same 12-month rule applies, but results are posted directly in CTIS workspace with new transparency controls.
• WHO ICTRP-linked registries: Generally aligned with WHO best practice guidance (12 months for summary disclosure).

It’s vital to track “primary completion” and “end-of-trial” definitions in the protocol, as these dates trigger posting obligations. Failure to recognize the right deadline often leads to unintentional non-compliance.

Essential Elements of Summary Results Submissions

Results posted to registries must adhere to standardized formats. While each registry has specific templates, most include:

• Participant Flow (including number enrolled, completed, withdrawn)
• Baseline Characteristics (age, sex, condition)
• Primary and Secondary Outcome Data
• Adverse Events Summary
• Statistical Analysis Description

For example, ClinicalTrials.gov requires a tabular display using XML format or results entry via PRS system, while CTIS accepts Word and PDF templates but may eventually move to structured data input. Tools like FDA’s ClinicalTrials.gov results templates can be used for consistency.

How to Format and Submit Results on ClinicalTrials.gov

Submission of results on ClinicalTrials.gov involves several steps via the PRS (Protocol Registration and Results System):

1. Login using your organization’s PRS account
2. Locate the trial (NCT number) under “Records”
3. Navigate to “Results Section” and enter all tabs (Participant Flow, Baseline, Outcome, AE)
4. Validate and fix errors as prompted by system checks
5. Mark the record as “Ready for Review”
6. Submit for QC review and track the submission status

Validation errors must be cleared before the record moves into the public domain. FDA recommends that sponsors allocate 3–4 weeks for this full cycle, including corrections.

How to Post Results in EudraCT and CTIS

For legacy trials under EudraCT, sponsors must use the EudraCT results submission portal and upload:

• XML summary results file
• Validator output (EMA XML validation tool)
• PDF with results, if applicable

In CTIS, the process differs. The Clinical Trial Sponsor Workspace allows direct upload of results documents in a specific trial folder. CTIS tracks each submission milestone and will issue system-level flags for missing documents or overdue timelines.

To read more on how CTIS compares with legacy EU registry systems, visit PharmaRegulatory.in.

Best Practices for Timely and Accurate Results Posting

Maintaining registry compliance is easier when sponsors adopt proactive practices. Some industry-tested strategies include:

• Develop an SOP that defines the responsibilities and timelines for results posting, especially highlighting roles for Data Management, Medical Writing, and Regulatory Affairs.
• Use results tracker tools to monitor upcoming deadlines and overdue postings across registries.
• Assign registry accountability to a single owner or team (e.g., Regulatory Operations or Clinical QA).
• Validate results content internally before registry upload to avoid errors and rejections.
• Capture confirmation emails/screenshots after successful posting for audit readiness.

Establishing these workflows early ensures consistency in multi-center or global trials where varying jurisdictional requirements must be harmonized.

Common Pitfalls and How to Avoid Them

Sponsors often encounter issues during results submission due to lack of internal controls. Common pitfalls include:

• Missing the deadline due to misidentification of trial completion dates
• Inadequate data formatting (e.g., decimals, confidence intervals)
• Non-conformance with registry templates
• Duplicate records or conflicting data between CTD and registry
• Failure to update record post-results (e.g., status, links)

These issues not only delay compliance but also create audit risks. Training staff and using mock QC checks of registry data can significantly reduce these failures.

Audit Trail and Documentation for Result Submissions

During inspections, regulatory authorities like the EMA and FDA may request evidence of when and how results were posted. Therefore, maintaining a robust audit trail is essential.

• Keep PDF printouts of the results page with date stamps
• Save validator output files (EudraCT) and XML versions (ClinicalTrials.gov)
• Maintain email confirmation from registry system
• Document internal QC checks and approval logs

This documentation should be filed in the TMF under the “Registry and Public Disclosure” section or within an eTMF with traceability metadata.

Conclusion

Posting clinical trial results is a legally binding requirement that reflects the sponsor’s commitment to transparency and compliance. From understanding timelines to mastering the formatting and submission processes across various registries, trial sponsors must integrate disclosure planning into every protocol lifecycle.

Adhering to global registry standards and maintaining comprehensive documentation helps prevent audit findings, regulatory delays, and reputational harm. To learn more about global trial disclosure workflows and access SOP templates, visit PharmaValidation.in or explore WHO publication guidelines at WHO.int.

Meeting U.S. Regulatory Requirements for Clinical Trial Results Disclosure

Introduction: The Importance of Posting Results

Results disclosure is a fundamental component of clinical trial transparency in the United States. While trial registration alerts the public to a study’s existence, posting trial results ensures that the findings—positive or negative—are available for patients, researchers, regulators, and healthcare professionals.

Under FDAAA 801 and the Final Rule (42 CFR Part 11), sponsors and responsible parties must post summary results for applicable clinical trials (ACTs) on ClinicalTrials.gov. Failure to comply can result in legal penalties, public notices of noncompliance, and loss of funding from government agencies like the NIH.

Who Must Report and What Is an Applicable Clinical Trial?

The obligation to disclose results falls on the “responsible party,” usually the trial sponsor or designated principal investigator. This includes:

• Drug, biologic, or device manufacturers sponsoring the study
• Academic institutions leading investigator-initiated trials
• Collaborative groups or consortia listed as sponsors or responsible parties

An Applicable Clinical Trial (ACT) is defined as a controlled clinical study (excluding most Phase I drug trials and small feasibility device studies) involving FDA-regulated products that are not exempt from IND or IDE requirements.

When Must Results Be Submitted?

Results for ACTs must be submitted within 12 months after the “Primary Completion Date”, which is the date when the final subject was examined or received an intervention for the purpose of final collection of data for the primary outcome measure.

In rare cases, responsible parties may request a delay or certification extension—for example, when FDA approval is pending—but these requests are time-bound and must be justified with supporting documentation.

What Must Be Included in Results Submissions?

ClinicalTrials.gov requires a structured and standardized results summary. The following modules must be completed:

• Participant Flow: Number of participants at each trial stage and reasons for dropout
• Baseline Characteristics: Demographics and baseline measures by arm/group
• Outcome Measures: Results for each pre-specified primary and secondary endpoint, including units and statistical analyses
• Adverse Events: Serious and other adverse events categorized by frequency and severity

All information must be entered into structured tables using ClinicalTrials.gov’s web-based submission system or through XML uploads via the Protocol Registration and Results System (PRS).

Adverse Events: Reporting Expectations

Reporting of adverse events is mandatory and includes two main tables:

1. Serious Adverse Events: Events that resulted in death, were life-threatening, required hospitalization, caused disability, or led to birth defects
2. Other (Non-Serious) Adverse Events: Events occurring at or above 5% frequency in any arm/group

Events must be categorized using MedDRA system organ class and preferred terms. If no events occurred, the table must still be submitted with a “0” entry to comply with formatting rules.

Quality Control and Posting Timeline

After submission, ClinicalTrials.gov conducts a Quality Control (QC) review, which typically takes 30–45 days. Sponsors will receive feedback and may need to revise and resubmit data if inconsistencies or missing fields are identified.

Once passed, the data is posted publicly and becomes searchable by the public. As of 2024, ClinicalTrials.gov lists the date results are submitted, posted, and revised, maintaining transparency of sponsor responsiveness.

Case Example: NIH-Funded Trial on Asthma

A multicenter trial funded by the NIH on asthma drug efficacy completed data collection in July 2023. The sponsor submitted results by July 2024 but failed initial QC due to incomplete outcome measure details.

After revision, results were posted in October 2024. Despite the delay, the sponsor avoided penalties by initiating submission on time and responding to QC comments promptly—highlighting the importance of early and complete submission.

Penalties for Late or Incomplete Reporting

The FDA has legal authority to enforce compliance with FDAAA 801. Penalties may include:

• Monetary fines up to $13,237 per day of noncompliance
• Public notices of violation listed on the FDA’s enforcement page
• Loss of eligibility for federal research grants
• Institutional damage to reputation and future partnerships

In 2021, the FDA issued over a dozen noncompliance notices, including to major universities and large CROs. Public enforcement has increased visibility into result posting performance.

Formatting and Common Pitfalls

Common issues that delay posting include:

• Inconsistent unit definitions across arms
• Failure to provide statistical analysis plans or p-values
• Missing denominators in AE tables
• Inadequate explanation of outcome time points

To avoid rejection, sponsors should prepare a results submission plan that mirrors the original protocol endpoints and statistical analysis methods, aligning submitted data with registered outcomes.

Best Practices for Results Disclosure Compliance

• Create a disclosure calendar aligned with your trial milestones
• Start results preparation before trial closeout using draft tables
• Assign roles to trained medical writers or disclosure leads
• Use validation tools provided by PRS to check format before submission
• Maintain internal QC reviews to catch issues prior to external QC

Larger organizations often implement SOPs and templates to streamline submissions and avoid inconsistencies across trial teams.

Conclusion: Transparency Begins with Results

Posting results on ClinicalTrials.gov is not a bureaucratic formality—it’s a legal, ethical, and scientific obligation. With increasing scrutiny from regulators, funders, and the public, trial sponsors must prioritize accuracy, timeliness, and completeness of their results submissions.

By understanding the FDAAA 801 requirements and building internal compliance structures, sponsors can not only avoid penalties but also contribute meaningfully to scientific progress and public trust in medical research.